Global Gamma Probe Market Size By Type (Handheld, Others), By Application (Hospital, Medical Center), By Region, And Segment Forecasts, 2023 to 2032

The Global Gamma Probe Market was valued at USD 112.6 million in 2023 and is projected to reach USD 203.7 million by 2031, growing at a CAGR of 7.5% during the forecast period (2023–2031). Gamma probes are specialized handheld devices used primarily in sentinel lymph node biopsies and radioguided surgeries. They are crucial in cancer diagnostics, particularly for breast cancer and melanoma, by helping surgeons detect radio-labeled lymph nodes with high accuracy. The growth of this market is primarily driven by the rising global cancer burden, technological advancements in nuclear medicine, and the increasing preference for minimally invasive surgical procedures.

Drivers:

1. Rising Incidence of Cancer:

The increasing prevalence of cancer worldwide, particularly breast cancer and melanoma, is a major driver for gamma probes, as these devices play a pivotal role in tumor localization and lymph node mapping.

2. Growing Demand for Minimally Invasive Surgeries:

Gamma probes are central to radioguided surgery, which minimizes tissue damage and accelerates recovery. The demand for such procedures is increasing due to lower post-operative complications and shorter hospital stays.

3. Technological Advancements in Nuclear Imaging:

Recent innovations such as wireless gamma probes, improved detector sensitivity, and hybrid probes integrating fluorescence or ultrasound are making procedures more efficient and boosting adoption across healthcare facilities.

Restraints:

1. High Equipment and Operating Costs:

The initial acquisition and maintenance cost of gamma probe systems can be high, particularly for healthcare institutions in developing regions, limiting widespread adoption.

2. Dependence on Radiopharmaceuticals:

The effectiveness of gamma probes is tied to the availability of radiopharmaceuticals like Technetium-99m. Disruptions in isotope supply or strict regulations can hinder routine procedures.

Opportunity:

1. Expansion in Emerging Healthcare Markets:

Countries across Asia-Pacific and Latin America are investing in cancer screening and surgical infrastructure. This opens opportunities for gamma probe manufacturers to enter new markets with cost-effective solutions.

2. Integration with Hybrid Imaging Technologies:

Developments in integrating gamma probes with intraoperative imaging platforms such as SPECT/CT and PET/CT provide surgeons with real-time anatomical and functional insights, enhancing procedural precision.

Market by System Type Insights:

The wired gamma probe segment held the largest market share in 2023 due to its reliability and cost-effectiveness. However, the wireless gamma probe segment is anticipated to grow at the highest CAGR during the forecast period. Wireless models offer greater maneuverability during surgery and reduce sterility concerns, aligning with the trend toward advanced minimally invasive technologies.

Market by End-use Insights:

In terms of end-use, hospitals and ambulatory surgical centers were the leading segment in 2023, driven by increasing patient preference for same-day procedures and the growing number of breast cancer surgeries. Research institutions are also showing rising demand as gamma probes become critical tools in nuclear medicine and oncology studies.

Market by Regional Insights:

North America dominated the gamma probe market in 2023, supported by advanced healthcare infrastructure, higher adoption of nuclear diagnostic techniques, and a well-established reimbursement framework. Asia-Pacific is expected to witness the fastest growth, driven by increasing healthcare investments, awareness campaigns for cancer screening, and the emergence of private oncology centers in countries like China and India.

Competitive Scenario:

Key players in the market include Devicor Medical Products (a Leica Biosystems company), SurgicEye GmbH, Intramedical Imaging LLC, Crystal Photonics GmbH, Care Wise Inc., and Capintec Inc. These companies are focused on product innovation, geographic expansion, and collaborations with nuclear medicine institutions.

In 2023, SurgicEye GmbH launched a gamma probe compatible with hybrid imaging tools, enhancing surgical navigation accuracy.

Intramedical Imaging received FDA clearance for its wireless gamma probe with dual-sensor technology in 2024, targeting outpatient oncology centers.

Devicor Medical expanded its distribution network in 2025 across Southeast Asia to meet the rising demand for radioguided surgical equipment.

Scope of Work – Global Gamma Probe Market

Report Metric Details

Market Size (2023) USD 112.6 million

Projected Market Size (2031) USD 203.7 million

CAGR (2023–2031) 7.5%

Market Segments By System Type (Wired, Wireless), By End-use (Hospitals, ASCs, Research Centers), By Region

Growth Drivers Rising global cancer incidence, preference for minimally invasive surgeries, technological advancements

Opportunities Emerging markets, hybrid imaging integration

Key Market Developments:

2023: SurgicEye GmbH launched a new gamma probe model integrated with surgical navigation software.

2024: Intramedical Imaging received regulatory approval for a wireless, high-sensitivity gamma probe targeting outpatient facilities.

2025: Capintec Inc. expanded R&D investments into AI-supported gamma probe guidance systems.

FAQs:

1. What is the current market size of the Global Gamma Probe Market?

The Global Gamma Probe Market was valued at USD 112.6 million in 2023.

2. What is the major growth driver of the Global Gamma Probe Market?

The major growth driver is the rising incidence of cancer and growing preference for minimally invasive radioguided surgeries.

3. Which is the largest region during the forecast period in the Global Gamma Probe Market?

North